FGAM
OCUL icon

Financial Gravity Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Financial Gravity Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$7 – 2101
2024
Q1 		$7 Buy
+1
New +$7 ﹤0.01% 1933
2023
Q3 		– Sell
-5
Closed -$11 – 1598
2023
Q2 		$11 Buy
+5
New +$30 ﹤0.01% 1525
2023
Q1 		– Sell
-3
Closed -$6 – 1487
2022
Q4 		$6 Buy
+3
New +$10 ﹤0.01% 1381

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Financial Gravity Asset Management's OCUL Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Ocular Therapeutix (OCUL) in Q2 2024, closing a stake of 1 share — an estimated $7 sold.

Financial Gravity Asset Management first reported a position in OCUL in Q4 2022 and held it in 3 quarters. The position peaked at $11 in Q2 2023. 150 funds tracked by Wall St. Rank hold OCUL as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Ocular Therapeutix position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 1 Ocular Therapeutix share in Q2 2024, an estimated $7.
  • Financial Gravity Asset Management first reported a position in Ocular Therapeutix in Q4 2022 and held it in 3 quarters.
  • Financial Gravity Asset Management's Ocular Therapeutix position peaked at $11 in Q2 2023.
  • 150 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.